{"id":"lower-albumin-dosage","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypervolemia / fluid overload"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albumin is a carrier protein used clinically for volume expansion, nutritional support, and drug delivery. Reducing the dosage lowers the total protein load administered intravenously, which may decrease the risk of hypervolemia, allergic reactions, and other albumin-related complications. This approach aims to optimize the risk-benefit profile in conditions where albumin therapy is indicated but high doses may be problematic.","oneSentence":"Lower albumin dosage reduces the amount of human serum albumin administered to patients, potentially minimizing exposure-related adverse effects while maintaining therapeutic benefit.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:41.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypovolemia or plasma volume expansion in critical illness or surgery"},{"name":"Hypoalbuminemia in liver disease or malnutrition"}]},"trialDetails":[{"nctId":"NCT06953323","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT07444541","phase":"PHASE1, PHASE2","title":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anova Innovation Limited","startDate":"2026-03","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":"Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":12},{"nctId":"NCT04680728","phase":"","title":"Venous Congestion and Organ Dysfunction.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-10-06","conditions":"Venous Congestion, Organ Dysfunction Syndrome","enrollment":185},{"nctId":"NCT05969171","phase":"PHASE2","title":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-05","conditions":"Pancreatic Cancer Metastatic","enrollment":65},{"nctId":"NCT07072572","phase":"PHASE3","title":"Lung Point of Care Ultrasound to Guide Albumin Administration in Cirrhosis","status":"COMPLETED","sponsor":"Centro Medico Issemym","startDate":"2023-03-01","conditions":"Cirrhosis, Cirrhosis Advanced, Acute Kidney Injury","enrollment":72},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT06892535","phase":"PHASE4","title":"Low-dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis (LVP) in Decompensated Cirrhosis Liver.","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2024-02-02","conditions":"Paracentesis-Induced Circulatory Dysfunction","enrollment":52},{"nctId":"NCT03410823","phase":"NA","title":"PUSH Plus Protein Pilot for Hip Fracture Patients","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2018-07-16","conditions":"Hip Fracture","enrollment":20},{"nctId":"NCT06499948","phase":"PHASE4","title":"Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)","status":"RECRUITING","sponsor":"Stefan Lujinschi","startDate":"2024-02-26","conditions":"Alport Syndrome, Thin Basement Membrane Disease, Alport Nephropathy","enrollment":34},{"nctId":"NCT04336098","phase":"PHASE1","title":"Study of SRF617 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2020-03-16","conditions":"Advanced Solid Tumor","enrollment":85},{"nctId":"NCT00499083","phase":"PHASE2","title":"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-05-01","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT05037162","phase":"PHASE2","title":"Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19","status":"COMPLETED","sponsor":"MGC Pharmaceuticals d.o.o","startDate":"2022-10-11","conditions":"Covid19, Corona Virus Infection","enrollment":240},{"nctId":"NCT04291690","phase":"NA","title":"The TARGET-EFT Randomized Clinical Trial","status":"COMPLETED","sponsor":"Jonathan Afilalo","startDate":"2020-03-05","conditions":"Frailty, Cardiovascular Diseases in Old Age, Geriatric Cardiology","enrollment":144},{"nctId":"NCT02910466","phase":"PHASE4","title":"A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism","status":"COMPLETED","sponsor":"Shire","startDate":"2016-10-27","conditions":"Chronic Hypoparathyroidism, Hypoparathyroidism","enrollment":39},{"nctId":"NCT04661696","phase":"PHASE2","title":"Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-12-09","conditions":"Ovarian Cancer","enrollment":75},{"nctId":"NCT00624650","phase":"PHASE2","title":"Hemodynamics and Extravascular Lung Water in Acute Lung Injury","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2008-02","conditions":"Acute Lung Injury","enrollment":33},{"nctId":"NCT00587990","phase":"PHASE1, PHASE2","title":"Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)","status":"TERMINATED","sponsor":"Joshua M Hare","startDate":"2007-11","conditions":"Stem Cell Transplantation, Ventricular Dysfunction, Left","enrollment":9},{"nctId":"NCT02120014","phase":"NA","title":"Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-04-21","conditions":"Congestive Heart Failure","enrollment":60},{"nctId":"NCT02449746","phase":"NA","title":"Study of Immunotherapy in Autoantibody Positive Psychosis","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2015-08","conditions":"Schizophrenia, Psychosis, Auto Immune Disorders","enrollment":10},{"nctId":"NCT03405350","phase":"NA","title":"Evaluation of Spa Medicine on the Example of Comprehensive Therapy in the Spa Resort Przerzeczyn Zdroj","status":"COMPLETED","sponsor":"Wroclaw Medical University","startDate":"2009-01","conditions":"Osteoarthritis, Degenerative Disc Disease","enrollment":127},{"nctId":"NCT00311090","phase":"PHASE3","title":"Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-04","conditions":"Deep Venous Thrombosis","enrollment":757},{"nctId":"NCT01946269","phase":"PHASE3","title":"Goal-Directed Therapy in Cancer Surgery","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2013-09","conditions":"Postoperative Care","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lung ultrasound guided administration of albumin"],"phase":"phase_3","status":"active","brandName":"Lower albumin dosage","genericName":"Lower albumin dosage","companyName":"Centro Medico Issemym","companyId":"centro-medico-issemym","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lower albumin dosage reduces the amount of human serum albumin administered to patients, potentially minimizing exposure-related adverse effects while maintaining therapeutic benefit. Used for Hypovolemia or plasma volume expansion in critical illness or surgery, Hypoalbuminemia in liver disease or malnutrition.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}